Fragasso Financial Advisors Inc Sells 47 Shares of Danaher Co. (NYSE:DHR)

Fragasso Financial Advisors Inc reduced its holdings in Danaher Co. (NYSE:DHR) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,099 shares of the conglomerate’s stock after selling 47 shares during the quarter. Fragasso Financial Advisors Inc’s holdings in Danaher were worth $252,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Benjamin Edwards Inc. increased its position in Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after buying an additional 38 shares during the period. Wedge Capital Management L L P NC increased its position in Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 38 shares during the period. Certified Advisory Corp raised its stake in Danaher by 4.5% during the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after purchasing an additional 40 shares during the last quarter. Meridian Financial Partners LLC boosted its holdings in Danaher by 4.4% in the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares during the period. Finally, Kovack Advisors Inc. grew its position in Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 2.0 %

NYSE DHR opened at $239.83 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a 52 week low of $222.53 and a 52 week high of $281.70. The stock has a market capitalization of $173.22 billion, a P/E ratio of 45.77, a price-to-earnings-growth ratio of 4.32 and a beta of 0.83. The stock has a fifty day moving average of $235.52 and a 200-day moving average of $253.65.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 EPS. On average, equities research analysts forecast that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Analysts Set New Price Targets

DHR has been the subject of several research reports. Guggenheim started coverage on shares of Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Robert W. Baird decreased their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research note on Friday, December 13th. Raymond James lowered their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.